Components	Microplate,WashBuffer,DilutionBuffer,PCSK9Standard,HRPconjugatedDetectionAntibody,SubstrateReagent,StopSolution
Intendeduse	ThisKitisusedforthequantitativemeasurementofHumanPCSK9inserum,plasma,cellculturemediumandotherBIOLOGicalmedia.
Storagetemp.	4°C	Manufacturer	MBL
Animalspecies [GeneID]	Human
Sample	Serum,Plasma,Cellculturemedium,Otherbiologicalmedia
Measurementrange	0.16～10ng/mL
Sensitivity	0.154ng/mL～
Citations	NoguchiTetal.TheE32KvariantofPCSK9exacerbatesthephenotypeoffamilialhypercholesterolaemiabyincreasingPCSK9functionandconcentrationinthecirculation.Atherosclerosis210,166-172(2010)(PMID:20006333) CariouBetal.AssociationbetweenplasmaPCSK9andgamma-glutamyltransferaselevelsindiabeticpatients.Atherosclerosis211,700-702(2010)(PMID:20452593) CostetPetal.PlasmaPCSK9isincreasedbyFenofibrateandAtorvastatininanonadditivefashionindiabeticpatients.Atherosclerosis212,246-251(2010)(PMID:20619837) NoguchiTetal.Comparisonofeffectsofbezafibrateandfenofibrateoncirculatingproproteinconvertasesubtilisin/kexintype9andADIpocytokinelevelsindyslipidemicsubjectswithimpairedglucosetoleranceortype2diabetesmellitus:Resultsfromacrossoverstudy.Atherosclerosis217,165-70(2011)(PMID:21411093) MayneJetal.NovelLoss-of-FunctionPCSK9VariantIsAssociatedwithLowPlasmaLDLCholesterolinaFrench-CanadianFamilyandwithImpairedProcessingandSecretioninCellCulture.ClinChem.57,1415(2011)(PMID:21813713) VergèsBetal.LackofassociationbetweenplasmaPCSK9andLDL-apoB100catabolisminpatientswithuncontrolledtype2diabetes.Atherosclerosis.219,342-8(2011)(PMID:21889145) LenaPersson.StudiesonPCSK9intheregulationofcholesterolmetabolism.PublishedbyKarolinskaInstitutet.Stockholm2011 CariouBetal.ClinicalaspectsofPCSK9.Atherosclerosis.216,258-65(2011)(PMID:21596380) PerssonLetal.EndogenousEstrogensLowerPlasmaPCSK9andLDLCholesterolButNotLp(a)orBileAcidSynthesisinWomen.ArteriosclerThrombVascBiol.32,810-4(2011)(PMID:22207727) KawashiriMAetal.EfficacyandSafetyofCoadmiNISTrationofRosuvastatin,Ezetimibe,andColestimideinHeterozygousFamilialHypercholesterolemia.AmJCardiol.109,364-9(2011)(PMID:22112743) LindholmMWetal.PCSK9LNAAntisenseOligonucleotidesInduceSustainedReductionofLDLCholesterolinNonhumanPrimates.MolTher.20,376-81(2012)(PMID:22108858) CameronJetal.Serumlevelsofproproteinconvertasesubtilisin/kexintype9insubjectswithfamilialhypercholesterolemiaindicatethatproproteinconvertasesubtilisin/kexintype9isclearedfromplasmabylow-densitylipoproteinreceptor_independentpathways.TranslationalResearch.160,125-30(2012)(PMID:22683370) HuijgenRetal.PlasmalevelsofproproteinconvertasesubtilisinKexintype9(PCSK9)andphenotypicvariABIlityinfamilialhypercholesterolemia.JLipidRes.53,979-83(2012)(PMID:22375030) CariouBetal.PlasmaPCSK9concentrationsduringanoralfatloadandaftershorttermhigh-fat,high-fathigh-proteinandhigh-fructosediets.NutrMetab.10,4(2013)(PMID:23298392) LeeCJetal.Associationofserumproproteinconvertasesubtilisin/kexintype9withcarotidintimamediathicknessinhypertensivesubjects.Metabolism.62,845-50(2013)(PMID:23380568) LeBrasMetal.PlasmaPCSK9isalatebioMarkerofseverityinpatientswithseveretraumainjury.JClinEndocrinolMetab.98,E732-6(2013)(PMID:23450051) MayneJetal.DifferentialeffectsofPCSK9lossoffunctionvariantsonserumlipidandPCSK9levelsinCaucasianandAfricanCanadianpopulations.LipidsHealthDis.12,70(2013)(PMID:23663650) PeticcaPetal.HumanSerumPCSK9IsElevatedatParturitioninComparisontoNonpregnantSubjectsWhileSerumPCSK9fromUmbilicalCordBloodisLowerComparedtoMaternalBlood.ISRNEndocrinol.2013,341632(2013)(PMID:23862071) TremblayAJetal.Short-term,high-fatdietincreasestheexpressionofkeyintestinalgenesinvolvedinlipoproteinmetabolisminhealthymen.AmJClinNutr.98,32-41(2013)(PMID:23719552) ConwayVetal.Impactofbuttermilkconsumptiononplasmalipidsandsurrogatemarkersofcholesterolhomeostasisinmenandwomen.NutrMetabCardiovascDis.23,1255-62(2013)(PMID:23786821) LambertGetal.ElevatedplasmaPCSK9levelisequallydetrimentalforpatientswithnonfamilialhypercholesterolemiaandheterozygousfamilialhypercholesterolemia,irrespectiveoflow-densitylipoproteinreceptordefects.JAmCollCardiol.63,2365-73(2014)(PMID:24632287) WernerCetal.Riskpredictionwithproproteinconvertasesubtilisin/kexintype9(PCSK9)inpatientswithstablecoronarydiseaseonstatintreatment.VasculPharmacol.62,94-102(2014)(PMID:24685817) AbujradHetal.ChronickidneydiseaseonhemodialysisisassociatedwithdecreasedserumPCSK9levels.Atherosclerosis.233,123-9(2014)(PMID:24529132) JiaYJetal.Short-andlong-termeffectsofXuezhikang(),anextractofcholestin,onserumproproteinconvertasesubtilisin/kexintype9levels.ChinJIntegrMed.(2014)(PMID:24993334) BondeYetal.ThyroidhormonereducesPCSK9andstimulatesbileacidsynthesisinhumans.JLipidRes.55,2408-15(2014)(PMID:25172631) MbikayMetal.Quercetin-3-glucosideincreaseslow-densitylipoproteinreceptor(LDLR)expression,attenuatesproproteinconvertasesubtilisin/kexin9(PCSK9)secretion,andstimulatesLDLuptakebyHuh7humanhepatocytesinculture.FEBSOpenBio.4,755-62(2014)(PMID:25349780) IggmanDetal.Roleofdietaryfatsinmodulatingcardiometabolicriskduringmoderateweightgain:arandomizeddouble-blindoverfeedingtrial(LIPOGAINstudy).JAmHeartAssoc.3,e001095(2014)(PMID:25319187) XuRXetal.RelationofplasmaPCSK9levelstolipoproteinsubfractionsinpatientswithstablecoronaryarterydisease.LipidsHealthDis.13,188(2014)(PMID:25496400) GhoshMetal.InfluenceofphysiologicalchangesinendogenousestrogenoncirculatingPCSK9andLDLcholesterol.JLipidRes.56,463-9(2015)(PMID:25535288) XuRXetal.ImpactsofezetimibeonPCSK9inrats:studyontheexpressionindifferentorgansandthepotentialmechanisms.JTranslMed.13,87(2015)(PMID:25889684) StarrAEetal.β-Estradiolresultsinaproproteinconvertasesubtilisin/kexintype9-dependentincreaseinlow-densitylipoproteinreceptorlevelsinhumanhepaticHuH7cells.FEBSJ.282,2682-96(2015)(PMID:25913303) RosqvistFetal.Potentialroleofmilkfatglobulemembraneinmodulatingplasmalipoproteins,geneexpression,andcholesterolmetabolisminhumans:arandomizedstudy.AmJClinNutr.102,20-30(2015)(PMID:26016870) ButkinareeCetal.AmyloidPrecursor-likeProtein2andSortilinDoNotRegulatethePCSK9Convertase-mediatedLowDensityLipoproteinReceptorDegradationbutInteractwithEachOther.JBiolChem.290,18609-20(2015)(PMID:26085104) vanPelgeestEPetal.Antisense-mediatedreductionofproproteinconvertasesubtilisin/kexintype9(PCSK9):afirst-in-humanrandomized,placebo-controlledtrial.BrJClinPharmacol.80,1350-61(2015)(PMID:26261033) WassefHetal.TheapoB-to-PCSK9ratio:Anewindexformetabolicriskinhumans.JClinLipidol.9,664-75(2015)(PMID:26350813) Si-TayebKetal.Urine-sample-derivedhumaninducedpluripotentstemcellsasamodeltostudyPCSK9-mediatedautosomaldominanthypercholesterolemia.DisModelMech.9,81-90(2016)(PMID:26586530) RogacevKSetal.PCSK9PlasmaConcentrationsAreIndependentofGFRandDoNotPredictCardiovascularEventsinPatientswithDecreasedGFR.PLoSOne11,e0146920(2016)(PMID:26799206) MiasanAetal.EffectsofLDLReceptorModulationonLymphaticFunction.SciRep.6,27862(2016)(PMID:27279328) VlachopopulosCetal.Predictionofcardiovasculareventswithlevelsofproproteinconvertasesubtilisin/kexintype9:Asystematicreviewandmeta-analysis.Atherosclerosis.252,50-60(2016)(PMID:27501130) LiSetal.Novelcirculatinglipidmeasurementsforcurrentdyslipidemiasinnon-treatedpatientsundergoingcoronaryangiography:PCSK9,apoC3andsdLDL-C.Oncotarget8,12333-12341(2017)(PMID:27713142) NavareseEPetal.AssociationofPCSK9withplateletreactivityinpatientswithacutecoronarysyndrometreatedwithprasugrelorticagrelor:ThePCSK9-REACTstudy.IntJCardiol.227,644-649(2017)(PMID:27810295) SuzukiYetal.BiodegradablelipidnanoparticlesinduceaprolongedRNAinterference-mediatedproteinknockdownandshowrapidhepaticclearanceinmiceandnonhumanprimates.IntJPharm.519,34-43(2017)(PMID:28089936) LiSetal.Novelandtraditionallipid-relatedbiomarkersandtheircombinationsinpredictingcoronaryseverity.SciRep.7,360(2017)(PMID:28336922) HyrinaAetal.Treatment-InducedViralCureofHepatitisCVirus-InfectedPatientsInvolvesaDynamicInterplayamongthreeImportantMolecularPlayersinLipidHomeostasis:CirculatingmicroRNA(miR)-24,miR-223,andProproteinConvertaseSubtilisin/KexinType9.EBioMedicine.23,68-78(2017)(PMID:28864162) BlanchardCetal.Roux-en-Ygastricbypassreducesplasmacholesterolindiet-inducedobesemicebyaffectingtrans-intestinalcholesterolexcretionandintestinalcholesterolabsorption.IntJObes.(2017)Inpress.(PMID:29135972)
Productcategory	Researcharea Metabolism Drugdiscovery

MBL泛素/蛋白酶体检测试剂盒泛素-蛋白酶体途径是真核细胞中蛋白水解的主要途径，除了降解胞质溶胶和细胞核中的异常蛋白外，还可能有助于控制多种短寿命蛋白的细胞内水平。蛋白质底物上标记有多泛素链，然后被存在于所有真核细胞中的大型多催化复合物蛋白酶体降解为肽和游离泛素。已经发现调节蛋白的许多实例经历遍在蛋白依赖性蛋白水解。泛素-蛋白酶体途径的蛋白质底物包括许多细胞调节分子，例如细胞周期蛋白，Myc癌基因蛋白和p53，这些分子的受控降解与细胞增殖和细胞周期进程的控制有关。通过控制这种蛋白质的细胞内水平，泛素-蛋白酶体途径的活性也可能与细胞凋亡有关。蛋白酶体富集和活性测定试剂盒　CycLex蛋白酶体富集和活性测定试剂盒用于细胞内蛋白酶体蛋白的分离和研究。通过使用hHR23B泛素样结构域树脂（UbL-Resin），从细胞或组织裂解物中分离20S蛋白酶体。结合的20S蛋白酶体蛋白酶活性可以通过荧光蛋白酶体底物（Suc-LLVY-AMC）来测量。此外，该试剂盒可用于研究20S蛋白酶体功能以及与其他蛋白质的相互作用。由于hHR23B中的泛素样结构域的氨基酸序列在哺乳动物中非常保守，因此该试剂盒可用于所有哺乳动物细胞。聚泛素化蛋白质富集和检测试剂盒　CycLex聚泛素化蛋白富集和检测试剂盒用于分离和研究细胞内聚泛素修饰的蛋白。通过使用聚泛素亲和树脂，可以从细胞或组织裂解物中分离出泛素化的蛋白质。然后可以从亲和树脂中洗脱结合的蛋白质，并使用抗聚泛素单克隆抗体进行分析。多泛素化蛋白质ELISA试剂盒　CycLex聚泛素化酶联免疫吸附试剂盒旨在检测和定量细胞裂解液中总聚泛素化蛋白的水平。由于遍在蛋白的氨基酸序列在哺乳动物中非常保守，因此该ELISA试剂盒可用于任何哺乳动物细胞。该测定法旨在检测细胞裂解物中的多泛素化蛋白。